Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)( 2 ) NDA in the United States
May 9, 2025Weston, Florida (May 09, 2025) – Apotex Corp. today launched IVRA™ (Melphalan) hydrochloride injection 90mg/ml multidose vial ("IVRA"), first ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)( 2 ) NDA in the United States.
IVRA is an alkylating drug indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate, and will be distributed primarily through hospital and institutional channels.
"The launch of IVRA highlights Apotex's uncompromising dedication to access, innovation, and patient care," said Christine Baeder, President, Apotex USA. "As we introduce our novel ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)( 2 ) NDA in the United States, we reinforce our commitment to bringing much-needed products that support patients on their health journeys."
Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications.
About Apotex
Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.
-30-
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.
-
Oct 5, 2026
Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, October 5, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today the closing of the previously announced offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 29, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.